TDS and UScellular to present at Citi AppsEconomy Conference
Get Alerts TDS Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.4%
EPS Growth %: -63.6%
Join SI Premium – FREE
CHICAGO, Dec. 30, 2021 /PRNewswire/ -- Telephone and Data Systems, Inc. (NYSE: TDS) and United States Cellular Corporation (NYSE: USM) are jointly presenting at Citi's 2022 Virtual AppsEconomy Conference on January 6, 2022 at 11:00 a.m. EST (10:00 a.m. CST). Laurent C. Therivel, President and CEO – UScellular; James W. Butman, President and CEO – TDS Telecom; Colleen Thompson, Vice President, Corporate Relations – TDS; and Jane W. McCahon, Senior Vice President, Corporate Relations – TDS will attend.
To listen to all presentations, please visit the events and presentations pages of investors.tdsinc.com or investors.uscellular.com. The presentation will be webcast both live and on-demand. It is recommended that you register at least 15 minutes before the start of the presentation to register, download and install any necessary multimedia streaming software.
About TDS
Telephone and Data Systems, Inc. (TDS), a Fortune 1000® company, provides wireless; broadband, video and voice; and hosted and managed services to approximately 6 million connections nationwide through its businesses, UScellular, TDS Telecom, and OneNeck IT Solutions. Founded in 1969 and headquartered in Chicago, TDS employed approximately 8,900 associates as of September 30, 2021.
For more information about TDS and its subsidiaries, visit:
TDS: www.tdsinc.comUScellular: www.uscellular.comTDS Telecom: www.tdstelecom.comOneNeck IT Solutions: www.oneneck.com
View original content:https://www.prnewswire.com/news-releases/tds-and-uscellular-to-present-at-citi-appseconomy-conference-301451682.html
SOURCE Telephone and Data Systems, Inc. and United States Cellular Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 2026 CSCCP-ASCCP Colposcopy Training Course--Wuhan Station Concludes, Promoting More Precise and Non-Invasive Management of Cervical Lesions
- Saab Q3 results 2026: Positioned to capture growing demand
- Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share